TScan Therapeutics (TCRX) has released an update to notify the public and investors about its officers.
TScan Therapeutics, Inc. announced the hiring of Jason A. Amello as Chief Financial Officer, effective January 29, 2024, with additional roles as Treasurer, principal financial officer, and principal accounting officer. With a background that includes CFO positions at several biotech firms and a tenure at Genzyme Corporation, Amello brings extensive experience to the role. His employment agreement includes a $500,000 base salary, equity incentives, and the potential for bonuses and severance benefits. Upon his appointment, previous interim officers returned to their original roles within the company.
For further insights into TCRX corporate activity, check out TipRanks’ Insiders Trading Activity page.
